Gemcitabine and docetaxel in metastatic, castrate-resistant prostate cancer

Cancer

Volumn 117, Issue 4, 2011, Pages 752-757

  Garcia, Jorge A ^a   Hutson, Thomas E ^b   Shepard, Dale ^a   Elson, Paul ^a   Dreicer, Robert ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

castrate resistant prostate cancer; chemotherapy; docetaxel; gemcitabine; prostate specific antigen

Indexed keywords

ANTIANDROGEN; DOCETAXEL; GEMCITABINE; GONADORELIN AGONIST; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CLINICAL ARTICLE; CONTINUOUS INFUSION; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; HUMAN; INFECTION; MALE; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA AND VOMITING; NEUTROPENIA; ORCHIECTOMY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; SIDE EFFECT; SKIN DISEASE; TASTE DISORDER; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIA; TREATMENT OUTCOME; CASTRATION RESISTANT PROSTATE CANCER; CONFERENCE PAPER; DISEASE SEVERITY; HYPERTRANSAMINASEMIA; NAUSEA; SURVIVAL TIME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CASTRATION; DEOXYCYTIDINE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TAXOIDS;

EID: 79551717840     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25457     Document Type: Article

References (20)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59: 225-249.
2. Oh WK, Kantoff PW,. Management of hormone refractory prostate cancer: current standards and future prospects. J Urol. 1998; 1160: 1220-1229.
3. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advance refractory prostate cancer. N Engl J Med. 2004; 351: 1513-1520.
4. Tannock IF, deWit R, Berry WR, et al. Docetaxel and prednisone or mitoxantrone and prednisone for advanced prostate cancer. N Engl J Med. 2004; 351: 1502-1512.
5. Wong A, Soo RA, Yong WP, Innocenti F,. Clinical pharmacology and pharmacogenetics of gemcitabine. Drug Metab Rev. 2009; 41: 77-88.
6. Muenchen H, Quigley M, Pilat M, et al. The study of gemcitabine in combination with other chemotherapeutic agents as an effective treatment for prostate cancer. Anticancer Res. 2000; 20: 735-740.
7. Morant R, Bernhard J, Maibach R, et al. Response and palliation in a phase II trial of gemcitabine in hormone-refractory metastatic prostatic carcinoma. Swiss Group for Clinical Cancer Res. (SAKK). Ann Oncol. 2000; 11: 183-188.
8. Mekhail T, Hutson T, Elson P, et al. Phase I trial of weekly docetaxel and gemcitabine in patients with refractory malignancies. Cancer. 2003; 97: 170-178.
9. Poole M, Bernard S, Churchel M, et al. A phase I study of gemcitabine and docetaxel for advanced stage solid tumors. Cancer Invest. 2003; 21: 350-354.
10. Dreicer R, Manola J, Schneider D, et al. Phase II trial of gemcitabine and docetaxel in patients with advanced carcinoma of the urothelium: a trial of the Eastern Cooperative Oncology Group. Cancer. 2003; 97: 2743-2747.
11. Niho S, Kubota K, Goto K, et al. Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent nonsmall-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial. Cancer Chemother Pharmacol. 2003; 52: 19-24.
12. Pouessel D, Culine S, Becht C, et al. Gemcitabine and docetaxel after failure of cisplatin-based chemotherapy in patients with carcinoma of unknown primary site. Anticancer Res. 2003; 23 (3C): 2801-2804.
13. Skarlos D, Dimopoulos A, Kosmidis P, et al. Docetaxel and gemcitabine combination, as first-line treatment, in patients with extensive disease small-cell lung cancer. A phase II study of the Hellenic Cooperative Oncology Group. Lung Cancer. 2003; 41: 107-111.
14. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
15. Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol. 2009; 27: 3742-3748.
16. Chen Y, Clegg NJ, Scher HI,. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 2009; 10: 981-991.
17. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009; 324: 787-790.
18. De Dosso S, Berthold DR,. Docetaxel in the management of prostate cancer: current standard of care and future directions. Exper Opin Pharmacother. 2008; 9: 1969-1979.
19. Buch-Hansen TZ, Bentzen L, Hansen S, et al. Phase I/II study on docetaxel, gemcitabine and prednisone in castrate refractory metastatic prostate cancer. Cancer Chemother Pharmacol. 2010; 66: 295-301.
20. Scher HI, Halabi S, Tannock I, et al. Design and endpoints of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol. 2008; 26: 1148-1159.